Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Chin, Kelly [VerfasserIn]   i
 Sitbon, Olivier [VerfasserIn]   i
 Doelberg, Martin [VerfasserIn]   i
 Feldman, Jeremy [VerfasserIn]   i
 Gibbs, J. Simon R. [VerfasserIn]   i
 Grünig, Ekkehard [VerfasserIn]   i
 Hoeper, Marius M. [VerfasserIn]   i
 Martin, Nicolas [VerfasserIn]   i
 Mathai, Stephen C. [VerfasserIn]   i
 McLaughlin, Vallerie V. [VerfasserIn]   i
 Perchenet, Loïc [VerfasserIn]   i
 Poch, David [VerfasserIn]   i
 Saggar, Rajan [VerfasserIn]   i
 Simonneau, Gérald [VerfasserIn]   i
 Galiè, Nazzareno [VerfasserIn]   i
Titel:Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension
Verf.angabe:Kelly M. Chin, Olivier Sitbon, Martin Doelberg, Jeremy Feldman, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Nicolas Martin, Stephen C. Mathai, Vallerie V. McLaughlin, Loïc Perchenet, David Poch, Rajan Saggar, Gérald Simonneau, Nazzareno Galiè
E-Jahr:2021
Jahr:27 September 2021
Umfang:11 S.
Fussnoten:Gesehen am 25.11.2021
Titel Quelle:Enthalten in: American College of CardiologyJournal of the American College of Cardiology
Ort Quelle:New York, NY : Elsevier, 1983
Jahr Quelle:2021
Band/Heft Quelle:78(2021), 14, Seite 1393-1403
ISSN Quelle:1558-3597
Abstract:Background - In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy. - Objectives - TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension; NCT02558231), a multicenter, double-blind, randomized phase 3b study, evaluated initial triple (macitentan, tadalafil, and selexipag) versus initial double (macitentan, tadalafil, and placebo) oral therapy in newly diagnosed, treatment-naive patients with PAH. - Methods - Efficacy was assessed until the last patient randomized completed week 26 (end of main observation period). The primary endpoint was change in pulmonary vascular resistance (PVR) at week 26. - Results - Patients were assigned to initial triple (n = 123) or initial double therapy (n = 124). At week 26, both treatment strategies reduced PVR compared with baseline (by 54% and 52%), with no significant difference between groups (ratio of geometric means: 0.96; 95% confidence interval: 0.86-1.07; P = 0.42). Six-minute walk distance and N-terminal pro-brain natriuretic peptide improved by week 26, with no difference between groups. Risk for disease progression (to end of main observation period) was reduced with initial triple versus initial double therapy (hazard ratio: 0.59; 95% confidence interval: 0.32-1.09). Most common adverse events with initial triple therapy included headache, diarrhea, and nausea. By the end of the main observation period, 2 patients in the initial triple and 9 in the initial double therapy groups had died. - Conclusions - In patients with newly diagnosed PAH, both treatment strategies markedly reduced PVR by week 26, with no significant difference between groups (primary endpoint not met). Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral therapy.
DOI:doi:10.1016/j.jacc.2021.07.057
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.jacc.2021.07.057
 Volltext: https://www.sciencedirect.com/science/article/pii/S0735109721058460
 DOI: https://doi.org/10.1016/j.jacc.2021.07.057
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:macitentan
 pulmonary arterial hypertension
 randomized controlled trial
 selexipag
 triple combination therapy
K10plus-PPN:1779080328
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68805261   QR-Code
zum Seitenanfang